Please wait...
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
Mesna is used to prevent bleeding in the bladder (hemorrhagic cystitis) during chemotherapy with ifosfamide (Ifex).
Mesna will not prevent other side effects caused by ifosfamide.
Mesna may also be used for purposes not listed in this medication guide.
Get emergency medical help if you have signs of a serious reaction: fever, nausea, vomiting, racing heartbeats, hives, rash or redness, skin pain or swelling, blisters or peeling, joint or muscle pain, feeling light-headed, trouble breathing, mouth sores, or swelling in your face or throat.
You should not use mesna if you are allergic to mesna, edetate sodium, sodium hydroxide, or benzyl alcohol.
Tell your doctor if you are allergic to any medicine.
Although mesna is not expected to harm an unborn baby, ifosfamide can harm an unborn baby if the mother or the father is using this medicine.
If you are a woman, you may need to have a negative pregnancy test before starting this treatment with ifosfamide. Use effective birth control to prevent pregnancy while you are using ifosfamide and for at least 6 months after your last dose.
If you are a man, use effective birth control if your sex partner is able to get pregnant. Keep using birth control for at least 3 months after your last dose of ifosfamide.
Tell your doctor right away if a pregnancy occurs while either the mother or the father is using ifosfamide.
Do not breast-feed while using mesna or ifosfamide, and for at least 1 week after your last dose.
Mesna injection contains an ingredient that can cause serious side effects or death in premature or low-birthweight babies. Mesna tablets do not contain this ingredient. Mesna injection should not be given to a premature or low birth weight infant.
Before and during treatment with mesna, you may need frequent urine tests.
Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.
Mesna injection is given as an infusion into a vein. A healthcare provider will give you this injection at the same time you receive ifosfamide.
Oral mesna is taken by mouth, usually 2 and 6 hours after you receive ifosfamide.
Mesna is given either in a series of 3 injections spaced 4 hours apart, or as a single injection followed by 2 oral doses spaced 2 and 6 hours later.
Follow your doctor's dosing instructions very carefully.
Call your doctor if you vomit within 2 hours after taking oral mesna. You may need to take another oral dose or receive a mesna injection.
Tell your doctor if you have red or pink colored urine. This may be a sign that your ifosfamide dose needs to be changed.
Drink at least 1 to 2 liters (32 to 64 ounces) of liquid each day while you are using mesna.
This medicine can affect the results of certain medical tests. Tell any doctor who treats you that you are using mesna.
Store mesna tablets at room temperature away from moisture and heat.
Call your doctor for instructions if you miss a dose of mesna.
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Follow your doctor's instructions about any restrictions on food, beverages, or activity.
Get emergency medical help if you have signs of an allergic reaction or severe skin reaction:
fever, nausea, vomiting, joint or muscle pain;
hives, rash or redness, skin pain or swelling, blisters or peeling;
feeling light-headed, trouble breathing;
racing heartbeats; or
mouth sores, or swelling in your face or throat.
Call your doctor at once if you have:
chest pain, trouble breathing;
easy bruising or bleeding (nosebleeds, bleeding gums);
low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or
low potassium level--leg cramps, constipation, irregular heartbeats, fluttering in your chest, increased thirst or urination, numbness or tingling, muscle weakness or limp feeling.
Common side effects may include:
nausea, vomiting, stomach pain, loss of appetite;
diarrhea, constipation;
weakness, tiredness, drowsiness;
headache;
hair loss; or
fever, flu-like symptoms.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Other drugs may affect mesna, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Mesna (www.drugs.com/mtm/mesna-oral-injection.html).
Applies to mesna: oral tablet
Other dosage forms:
Along with its needed effects, mesna may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking mesna:
More common
Less common
Incidence not known
Some side effects of mesna may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
Less common
Incidence not known
Applies to mesna: injectable solution, intravenous kit, oral tablet
Very common (10% or more): Nausea (65%), vomiting (35%), constipation (28%), anorexia (21%), abdominal pain/colic (14%), diarrhea
Common (1% to 10%): Dyspepsia, dehydration, anorexia, mucosal irritation, flatulence, burning pain (substernal/epigastric), gingival bleeding
Frequency not reported: Dry mouth, bad taste
Postmarketing reports: Dysgeusia
Very common (10% or more): Leukopenia (25%), thrombocytopenia (21%), anemia (20%), granulocytopenia (16%)
Common (1% to 10%): Lymphadenopathy
Frequency not reported: Activated partial thromboplastin time prolonged
Postmarketing reports: Decrease in lymphocyte count (generally reversible within one week)
Very common (10% or more): Lightheadedness, lethargy/drowsiness
Common (1% to 10%): Dizziness, headache, pain, somnolence, paresthesia, hyperesthesia, syncope, hypoesthesia, attention disturbance
Postmarketing reports: Convulsion
Very common (10% or more): Chest pain (10%)
Common (1% to 10%): Hypotension, tachycardia, palpitations
Postmarketing reports: Hypertension
Common (1% to 10%): Back pain, arthralgia, myalgia, pain in extremity, pain in jaw
Frequency not reported: Rigors
Very common (10% or more): Hypokalemia (10%)
Frequency not reported: Acute renal failure
Very common (10% or more): Fatigue (24%), fever (24%), asthenia (15%), flushing
Common (1% to 10%): Edema, peripheral edema, facial edema, pallor, insomnia, nightmares
Frequency not reported: Fever, malaise
Very common (10% or more): Alopecia (12%), rash
Common (1% to 10%): Hyperhidrosis, pruritus
Frequency not reported: Erythema multiforme, drug rash, ulcerations and/or bullae/blistering, angioedema, urticaria, burning sensation, erythema
Common (1% to 10%): Hematuria, dysuria
Postmarketing reports: Hepatitis
Common (1% to 10%): Pneumonia
Frequency not reported: Influenza-like symptoms
Very common (10% or more): Infusion site pruritus, infusion site rash
Common (1% to 10%: Infusion site pain, infusion site erythema, infusion site urticaria, infusion site swelling
Common (1% to 10%): Conjunctivitis, photophobia, blurred vision
Common (1% to 10%): Anxiety, confusion
Very common (10% or more): Dyspnea (11%)
Common (1% to 10%): Cough, nasal congestion, pleuritic pain, bronchospasm, laryngeal discomfort, epistaxis
Frequency not reported: Pharyngitis, rhinitis, respiratory distress, hypoxia
Postmarketing reports: Hemoptysis
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Mesna (www.drugs.com/mtm/mesna-oral-injection.html).
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
March 28, 2020
